313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms oleh Xiaoyu Zhang, Sanjeev Kaul, Paul Moore, Jason Luke, Bartosz Chmielowski, Hedy Kindler, Francine Chen, George Blumenschein, Erika Hamilton, Shakeela Bahadur, Cesar Santa-Maria, Janine Koucheki, Jichao Sun, John Muth, Patrick Kaminker, Bradley Sumrow